Trial Profile
Phase I study of intrathecal 131-I-3F8 monoclonal antibody [iodine I 131 monoclonal antibody 3F8] in patients with GD2 positive leptomeningeal neoplasms
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3F8 I-131 (Primary) ; Monoclonal antibody 3F8 I-131 (Primary)
- Indications Cancer; CNS cancer; Glioma; Malignant melanoma; Medulloblastoma; Meningeal carcinomatosis; Neuroblastoma; Retinoblastoma; Sarcoma; Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 24 Sep 2005 New trial record.